TheraRadar
Data updated: May 26, 2026

Adynovate (antihemophilic factor (recombinant), pegylated)

Approved 2015-11-12
1
Indication
--
Phase 3 Trials
10
Years on Market

Adynovate Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2015 to 2015
Nov 2015 ORIGINAL
Update · CBER biologic (Purple Book)

What Adynovate Treats

1 FDA approvals

Originally approved for its first indication in 2015 .

  • Other (1)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT04690322 STU-2020-1378 Ph 4 withdrawn POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
NCT05707351 results posted TAK-660-3001 2023-000502-26 Ph 3 completed A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Adynovate FDA Label Details

Track Adynovate with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.